(Reuters) – Merck & Co said on Wednesday it will supply about 60,000-100,000 doses of its COVID-19 treatment to the U.S. government for up to about $356 million.
The agreement will help support advanced development and large-scale manufacturing of Merck’s investigational therapeutic MK-7110 to treat hospitalized patients with severe or critical COVID-19, The U.S. Department of the Health and Human Services said.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Bernard Orr)
